By Adriano Marchese
Canopy Growth shares fell as a decline in Canadian adult-use cannabis weighed heavily on the company's revenue in the second fiscal quarter, days after an industry-wide collapse in cannabis stocks.
Shares traded 7.8% lower at 5.81 Canadian dollars ($4.19).
The Smiths Falls, Ontario-based cannabis company reported a 9% decline in total revenue to C$63 million, missing consensus expectations of C$64.2 million, according to FactSet.
Canopy saw a significant decline in Canadian adult-use cannabis, where revenue fell 24% to C$18.4 million. This offset the 16% gain from Canadian medical cannabis which reached C$18.7 million, and international markets cannabis which rose 12% to C$10.1 million.
The decline follows recent industry-wide pullback in cannabis stocks, in which Canopy wasn't spared, after initiatives to legalize recreational marijuana in Florida, North Dakota and South Dakota failed to receive enough votes.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
November 08, 2024 10:50 ET (15:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。